Mandelic Acid

Mandelic Acid

SCHEMBL810372

O=C(O)C(O)c1ccccc1.O=C(O)c1cccnc1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.68
APP P05067 1/20 0.68
GAA P10253 1/20 0.68
HCAR3 P49019 1/20 0.68
HCAR2 Q8TDS4 1/20 0.68
LMNA P02545 4/20 0.58
MAPK1 P28482 1/20 0.58
EPHX2 P34913 2/20 0.50
PLOD2 O00469 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
HTT P42858 1/20 0.48
KMO O15229 1/20 0.47
NAMPT P43490 1/20 0.47
F7 P08709 1/20 0.47
F3 P13726 1/20 0.47
SARM1 Q6SZW1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mandelic Acid SCHEMBL580052 0.88 F7 (0.67) ALDH1A1APPGAAHCAR3HCAR2
Diphenylacetic Acid SCHEMBL3208569 0.85 ALDH1A1 (0.70) ALDH1A1APPGAAHCAR3HCAR2
SCHEMBL11065543 0.83 LMNA (0.67) ALDH1A1APPGAAHCAR3HCAR2
Cadaverine Tartrate SCHEMBL219351 0.83 ALDH1A1 (0.78) ALDH1A1APPGAAHCAR3HCAR2
SCHEMBL2684159 0.83 SMN1; SMN2 (0.60) ALDH1A1APPGAAHCAR3HCAR2
SCHEMBL197024 0.83 SMN1; SMN2 (0.60) ALDH1A1APPGAAHCAR3HCAR2
SCHEMBL10170624 0.83 SMN1; SMN2 (0.60) ALDH1A1APPGAAHCAR3HCAR2
SCHEMBL31404936 0.83 SMN1; SMN2 (0.60) ALDH1A1APPGAAHCAR3HCAR2
Benzoic Acid SCHEMBL1008425 0.82 ALDH1A1 (0.91) ALDH1A1APPGAAHCAR3HCAR2
Niacin SCHEMBL3081560 0.82 ALDH1A1 (1.00) ALDH1A1APPGAAHCAR3HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113367375-A Fragrance-carrying supermolecule gel based on racemic mandelate nicotine salt gelling agent with equal pH ratio 云南中烟工业有限责任公司 2021-09-10 CN claimed
CN-113208148-A Supramolecular gel for synergistically releasing nicotine and aroma components 云南中烟工业有限责任公司 2021-08-06 CN claimed
CN-113208148-B Supramolecular gel for synergistically releasing nicotine and aroma components 云南中烟工业有限责任公司 2022-11-04 CN disclosed
CN-113367375-A Fragrance-carrying supermolecule gel based on racemic mandelate nicotine salt gelling agent with equal pH ratio 云南中烟工业有限责任公司 2021-09-10 CN disclosed
CN-113208148-A Supramolecular gel for synergistically releasing nicotine and aroma components 云南中烟工业有限责任公司 2021-08-06 CN disclosed
US-20160220536-A1 USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION UNIV OHIO (US) 2016-08-04 US disclosed
US-9326972-B2 Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression OHIO UNIVERSITY (US) 2016-05-03 US disclosed
US-20120238610-A1 Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression OHIO UNIVERSITY 2012-09-20 US disclosed
EP-2399578-A1 Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors The Interthyr Corporation (US) 2011-12-28 EP disclosed
US-20100004304-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER OHIO UNIVERSITY 2010-01-07 US disclosed
EP-1896015-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS The Interthyr Corporation (US) 2008-03-12 EP disclosed
WO-2006124676-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS THE INTERTHYR CORPORATION (US) 2006-11-23 WO disclosed
US-20060211752-A1 Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) 2006-09-21 US disclosed
US-20060147508-A1 Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes BIODERM RESEARCH (US) 2006-07-06 US disclosed
US-20040081672-A1 Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging GUPTA SHYAM K (US) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211752-A1 Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression TLR3, IRF3, TLR4 ALDH1A1 3364/4885APP 2349/4885GAA 4730/4885
US-20120238610-A1 Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression IRF3, TLR3, TLR4 ALDH1A1 3709/4885APP 3351/4885GAA 4660/4885
US-20160220536-A1 USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION IRF3, TLR3, TLR4 ALDH1A1 3709/4885APP 3351/4885GAA 4660/4885
US-20100004304-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER STAT3, STAT6, TLR3 ALDH1A1 2982/4885APP 4660/4885GAA 4770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.